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a b s t r a c t
A follow-up study was conducted to determine the magnitude of and factors related to
adherence to artemether/lumefantrine (ALu) treatment in rural settings in Tanzania. Children in ﬁve villages of Kilosa District treated at health facilities were followed-up at their
homes on Day 7 after the ﬁrst dose of ALu. For those found to be positive using a rapid
diagnostic test for malaria and treated with ALu, their caretakers were interviewed on drug
administration habits. In addition, capillary blood samples were collected on Day 7 to determine lumefantrine concentrations. The majority of children (392/444; 88.3%) were reported
to have received all doses, in time. Non-adherence was due to untimeliness rather than
missing doses and was highest for the last two doses. No signiﬁcant difference was found
between blood lumefantrine concentrations among adherent (median 286 nmol/l) and nonadherent [median 261 nmol/l; range 25 nmol/l (limit of quantiﬁcation) to 9318 nmol/l].
Children from less poor households were more likely to adhere to therapy than the poor
[odds ratio (OR) = 2.45, 95% CI 1.35–4.45; adjusted OR = 2.23, 95% CI 1.20–4.13]. The high
reported rate of adherence to ALu in rural areas is encouraging and needs to be preserved
to reduce the risk of emergence of resistant strains. The age-based dosage schedule and
lack of adherence to ALu treatment guidelines by health facility staff may explain both
the huge variability in observed lumefantrine concentrations and the lack of difference in
concentrations between the two groups.
© 2011 Royal Society of Tropical Medicine and Hygiene. Published by Elsevier Ltd.
All rights reserved.

1. Introduction
In 2006, Tanzania switched from sulfadoxine/
pyrimethamine (SP) to artemether/lumefantrine (ALu) as
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the ﬁrst-line treatment recommended for uncomplicated falciparum malaria. The limited availability of
ALu, combined with its rapid onset of action and rapid
clearance of severe clinical symptoms, might tempt
caretakers to discontinue treatment prematurely1 and
to keep the remaining medicine for an ‘anticipated’ next
attack.2 This may accelerate the pace of development
of drug resistance,3 thus making it important to maintain high adherence rates to preserve the efﬁcacy of
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artemisinin-based combination therapy (ACT) in Africa
and elsewhere.4
Adherence levels as high as 90% have been reported in
controlled clinical trials.5,6 These ﬁgures are likely to be
an overestimation because in real-life situations caretakers
are neither given detailed instruction on to how to administer the treatment nor do they receive follow-up on the
use of the drugs by the child.
Two community-based Tanzanian studies conducted
in Kilombero/Ulanga Districts and Zanzibar Islands did
report high levels of adherence to ACT treatment regimens
(77% and 99%, respectively).7,8 However, more information on adherence to ALu is required in order to inform
the implementation of drug policy change, given the low
access to ALu in rural remote areas.9 Community-based
data collected under real-life settings are also required in
order to estimate the level of community effectiveness,10,11
which reﬂects the success of implementation of a drug policy change.
Several factors have been reported to inﬂuence adherence to treatment, including: education of caretakers and
the use of pre-packaged co-blister packets12,13 ; drug efﬁcacy and rapid improvement of symptoms1,3,14 ; local
perceptions about the disease15 ; and caretakers perceiving a child playing after a single dose as a sign of cure.16
Most of these ﬁndings, however, are based on studies performed in Asia or during the time when chloroquine (CQ)
and SP were the ﬁrst-line recommended drugs.7,8 This
community-based study was therefore conducted to determine the level of and factors inﬂuencing adherence to ALu
among under-ﬁves in a real-life situation in rural Tanzania.
Information from this study will be important in designing appropriate implementation programmes for ACT in
Tanzania and elsewhere in Africa.5
2. Materials and methods
2.1. Study site
A 12-month follow-up study was conducted in June
2008 in Kilosa District, Tanzania. A detailed description of
the district is reported elsewhere.9 Malaria accounts for
more than one-half of clinical presentations by patients
attending the outpatient clinics and 60% of deaths among
under-ﬁve hospital admissions (district annual report,
2008). The health facilities are organised at three levels,
with 61 dispensaries that are at the lowest contact level,
seven health centres at the middle, and two hospitals as
well as a district hospital at the highest level. Only hospitals and health centres have a functioning microscope for
malaria diagnosis. Dispensaries have a catchment population of approximately 10 000 people, manned by a clinician
and a public health nurse, and serve the majority of the
children suspected to have uncomplicated malaria.
2.2. Study design and sample size
This was a follow-up observational study. Stratiﬁed
cluster sampling was carried out. All 30 rural villages listed
as rural in the National Census Report, 2003, located in
the wet-lowland areas, were grouped into those with and

without a health facility. One village among 12 villages with
a health facility and two villages among 18 villages without
a health facility were randomly selected using EPI Info v.6
(CDC, Atlanta, GA, USA). The rationale of 1:2 was based on
the proportion of villages with health facilities in the district. During the course of data collection, it was necessary
to compare between rural and semi-urban villages. Thus,
the ward headquarters of the three rural villages located
in semi-urban areas were included in the study. Two of
the initial villages shared the same ward; therefore, two
semi-urban villages were added making the total number
of study villages equal to ﬁve (Figure 1).
The unadjusted sample size was calculated as 280 based
on the assumption that 24% of caretakers would adhere to
treatment, as reported in a study in Uganda.11 Although
this study was based on CQ treatment, this was the most
recent adherence study in a setting similar to Tanzania.
A maximum 95% CI of ±5% was required, and adding
10% for possible loss to follow-up and another 27% as a
correction factor for clustering effect (intracluster correlation coefﬁcient = 0.01), the sample size was calculated as
391, approximated to 400. Based on Tanzanian studies, it
was assumed that approximately 80–90%17,18 of children
with fever would be treated at health centres or dispensaries. Data collection was planned to be completed in a
4-month period. However, during the study it was found
that most caretakers residing in villages without a health
facility sought care from drug vendors and ordinary shops
instead.9 Consequently, it took 12 months to recruit the
required sample size.
2.3. Data collection
Three research assistants (RA) were purposely recruited
both to administer the questionnaire and to take blood
samples. They were taught for 6 days on how to administer
the questionnaire and take blood samples.
At the time of the study, there were only three health
facilities in the study area that provided ALu, all of which
were public facilities. Therefore, these health facilities
acted as enrolment centres where RAs identiﬁed the names
of children who met the enrolment criteria from the laboratory and outpatient registers.
The enrolment criteria of children for the study were:
• child aged 3–59 months;
• child diagnosed at the health facility as positive for
malaria using a rapid diagnostic test (RDT);
• child prescribed with the correct dose of ALu according to
national treatment guideline, which is based on weight
and age, twice daily for 3 days19 ; and
• child resided in one of the ﬁve selected villages.
RAs traced the children home on Day 7 after the ﬁrst
dose of ALu. Recruitment of children into the study was
performed after a caretaker had provided written informed
consent. Caretakers were not given prior information about
the follow-up. Caretakers were interviewed regarding the
instructions received at the facility, the day and time they
administered the drugs, whether food was taken with the
drugs, whether food was cooked with oil, and whether
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All villages in wet-lowland
area (30) selected from a total
of 161 villages in the district

12 villages with health
facilities

Village 1
(rural)

18 villages without health
facilities

Village 2
(rural)

Village 3
(rural)

Village 4
(semi-urban)

Health facility 1
(serves Village
4)

Village 5
(semi-urban)

Health facility 2
(serves Village
1)

Health facility 3
(serves Villages 2, 3
and 5)

Figure 1. Overview of the process to recruit 5 out of 161 villages and study subjects (n = 446) in Kilosa District, Tanzania.

the child vomited, and if so, how soon after the drug
intake. (The questionnaire can be obtained from the corresponding author upon request.) Two caretakers could not
remember the events and were excluded from the analysis.
In addition, baseline data on demographic and socioeconomic status (SES) and knowledge about malaria treatment
were obtained. The questionnaire was based on a literature
review of previous adherence studies.6,11 A pilot study was
carried out for 1 week in two villages to validate the questionnaire and to gain ﬁeld experiences in blood sampling
techniques.
2.3.1. Deﬁnition of adherence to
artemether/lumefantrine treatment schedule
Adherence to treatment with ALu was deﬁned as a caretaker reported to have administered two doses daily for 3
days; if the ﬁrst dose was started in the evening, then one
dose on the ﬁrst day, two doses for 2 days and the last dose
on the fourth day, in the morning. The dose was one tablet
of ALu (20 mg artemether and 120 mg lumefantrine) for a
child aged <3 years and two tablets (artemether 40 mg and
lumefantrine 240 mg) for a child aged ≥3 years.
2.4. Blood sampling, handling and drug sample analysis
RAs collected capillary blood samples from the children on Day 7 through a ﬁnger-prick using the method
previously described by Ntale et al.20 After drying the ﬁlter paper, the specimen was stored in a plastic envelope
to avoid contamination and was collected by the supervisors weekly. Filter paper samples were stored at room
temperature for 3–15 months at the Pharmacology Laboratory of Muhimbili University (Dar es Salaam, Tanzania)
before transfer to the Clinical Pharmacology Laboratory

at Karolinska Institutet (Stockholm, Sweden) where blood
lumefantrine concentrations were determined by HPLC as
described by Ntale et al.20 Samples were assayed with an
intra-assay and inter-assay coefﬁcient of variation of <9.2%
and with a limit of quantiﬁcation (LoQ) of 25 nmol/l.
At the time of the study, several pilot studies were ongoing in the country aimed at rolling out of RDTs for malaria.
We therefore introduced RDTs for malaria diagnosis in the
three facilities, since Kilosa was not one of the pilot districts. Health workers in each facility and village health
workers in two dispensaries that were understaffed were
trained in performing the RDT for malaria. A 1-day training
course was held followed by 2 days of work under supervision. The tests were performed routinely for all children
under ﬁve with a suspected malaria diagnosis irrespective
of whether they resided in the ﬁve study villages or not.
The RDT called Paracheck (Orchid Biomedical Systems, Goa,
India) was obtained through donation from the National
Malaria Control Programme.
2.5. Data analysis
Data were double-entered into EpiData 3.0 (EpiData
Association, Odense, Denmark) before being transferred to
Stata v.10.1 (StataCorp., College station, TX, USA). Bivariate
analysis was performed on variables thought to inﬂuence
adherence to treatment with ALu. Variables found to be
associated were introduced in a stepwise multiple regression model using a cut-off point of 0.10. The variables were:
knowledge of treatment of severe malaria; SES; and intake
of food with oil. Marital status and age of the child were
also included. The variables SES and intake of food with oil
remained in the ﬁnal regression model; these were tested
for interaction and no association was found. SES was
calculated using principal component analysis in which
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Table 1
Background demographic characteristics of children under ﬁve enrolled in the study and their caretakers by reported adherence status (n = 444)
Characteristic of parent or child
Caretaker’s age (years)
<30
≥30
Child’s age (years)
<2
≥2
Child’s sex
Male
Female
Caretaker’s marital status
Not married
Married
Caretaker’s education (years)
<7
≥7
Residence
Rural
Semi-urban
Village status
Without a health facility
With a health facility
Overall

Reported non-adherence
n (%)

Reported adherence
n (%)

Total

P-value

32 (12.3)
20 (10.9)

228 (87.7)
164 (89.1)

260
184

0.642

26 (14.1)
26 (10.0)

159 (85.9)
233 (90.0)

185
259

0.195

30 (13.7)
22 (9.8)

189 (86.3)
203 (90.2)

219
225

0.199

34 (14.3)
18 (8.7)

204 (85.7)
188 (91.3)

238
206

0.070

25 (13.4)
27 (10.5)

162 (86.6)
230 (89.5)

187
257

0.354

40 (12.5)
12 (9.8)

281 (87.5)
111 (90.2)

321
123

0.428

22 (13.0)
30 (10.9)
52 (11.7)

147 (87.0)
245 (89.1)
392 (88.3)

169
275
444

0.502

19 assets adopted from the Tanzania Demographic Health
Survey were used.21 Variables that had ≥90% of the study
children in one category were excluded. The ﬁnal list
included household construction material composing walls
and the roof; the source of drinking water and type of light;
and ownership of a watch or clock, radio, mattress, a bednet and a bicycle. The ﬁrst component explained 30% of
the variability and was used to construct a SES index. The
SES index was categorised in ﬁve quintiles, and households
in the ﬁrst and second quintiles were classiﬁed as poor and
the others as less poor. Crude and adjusted odds ratios (OR)
with 95% CIs were reported.
Blood lumefantrine concentrations were found to have a
positive skewed distribution. Hence, log-transformed values of lumefantrine concentrations were used for statistical
testing of difference in mean levels (t-test) between children who adhered to therapy and those who did not. The
original concentration levels were also described using
medians and box plot. Before and after comparison of blood
lumefantrine concentrations could not be done because
this was an observational study that aimed at determining adherence to ALu under real-life conditions. Blood
sampling for determination of lumefantrine concentrations
was not done routinely at the health facilities. Permission to
conduct the study was obtained from the regional and district authorities. Written informed consent was obtained
prior to interviews from each adult caretaker during baseline data collection. All caretakers approached provided
informed consent for the study, except 18 who refused to
have a blood sample taken from their children.

children were not included because they were not found
at home (70), they were >5 years of age (2), they did not
receive ALu (4) or they had died (1). Blood samples for
lumefantrine concentrations were collected on Day 7 from
446 children; blood samples could not be collected from
21 children because their caretakers refused (18), the RAs
failed to draw a second sample after the ﬁrst attempt failed
(2) or the capillary tube broke (1). Two caretakers could
not recall most of the information; therefore, analysis was
carried out based on the 444 children who had complete
data.
Table 1 demonstrates no difference in sociodemographic characteristics between children who adhered to
ALu treatment and those who did not. More than one-half
of the children (58.3%) were aged ≥2 years and over onehalf of the caretakers (57.9%) had at least primary level
education.
The level of reported adherence to ALu was high
(392/444; 88.3%). Figure 2 shows that the number of

3. Results
A total of 544 names of eligible children were identiﬁed at the health facilities, 467 of whom were found on
Day 7 and their caretakers interviewed; 77 (14.2%) of the

Figure 2. Reported percent adherence rate by caretakers for each of the
six doses and cumulative adherence from the ﬁrst to sixth dose (n = 444).
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Table 2
Logistic regression analysis of factors inﬂuencing adherence to artemether/lumefantrine (ALu) among children under ﬁve in Kilosa District, Tanzania
(n = 444)
Factor
Access to healthcare services
Child’s age ≥2 years
Married
Caretaker’s basic education ≥7 years
Residing in semi-urban area
Using own or hired bicycle to go to health facility
Distance <5 km from a government facility
Knowledge on malaria
Knowledge that mosquitoes cause malaria
Knowledge that high fever causes convulsion in children
Knowledge of treatment of severe malaria
Knowledge that dawa mseto (ALu) is the recommended drug for the
treatment of malaria ya kawaida (uncomplicated malaria)
Socioeconomic status
Less poor (quintiles 3–5)
Other factors
History of vomiting during malaria episode
Taken food with oil
Taken adequate amount of food
Sought treatment same or next day

OR

95% CI

1.47
1.74
1.32
1.32
1.16
1.46

0.82–2.61
0.95–3.19
0.74–2.35
0.67–2.60
0.58–2.29
0.81–2.63

1.65
1.41
0.45
0.73

0.65–4.17
0.76–2.60
0.20–1.01
0.39–1.37

2.45

1.35–4.45

0.68
4.62
1.08
0.97

0.22–2.06
2.53–8.41
0.59–1.98
0.51–1.85

Adjusted OR

95% CI

1.80
1.87

0.90–3.58
0.90–3.88

2.23

1.20–4.13

4.60

2.49–8.50

OR: odds ratio.

4. Discussion
This study has shown a high (88%) level of reported
adherence to ALu treatment under real-life settings, contrary to fears that efﬁcacy observed in controlled trials
might not be reﬂected in real-life situations.22 Similar ﬁndings were reported in studies performed in Kilombero/
Ulanga Districts and in Zanzibar Islands, Tanzania, despite

some methodological differences. Whereas these studies included patients residing closer to health facilities
(5–6 km from health facilities), mostly in urban and semiurban areas and applied presumptive malaria diagnosis,9
the current included children from rural remote areas
(up to 25 km away) where the burden of malaria is the
highest.23
Therefore, the current study conﬁrms a high adherence to ALu among under ﬁves diagnosed to have malaria
using a RDT even in most rural settings remote from health
facilities.
No signiﬁcant difference in blood lumefantrine concentrations was found between children reported to adhere
to therapy and those who did not, in line with a study
in Malawi24 but contrary to a study in Uganda.6 One of
the reasons for the lack of any difference might be due
to the lack of a clear cut-off point.24 Although a previous study in Thailand reported a Day 7 blood lumefantrine

Blood lumefantrine concentration (nmol/l)

children who were reported to have taken all doses, in time,
was lowest for the last two doses.
When controlling for other factors, children from less
poor households were more likely to report adherence to
ALu treatment compared with the poor (OR = 2.45, 95% CI
1.35–4.45; adjusted OR = 2.23, 95% CI = 1.20–4.13) (Table 2).
Children who took food with oil were also more likely
to adhere to ALu treatment compared with those who
did not (OR = 4.62, 95% CI 2.53–8.41; adjusted OR = 4.60,
95% CI 2.49–8.50). Caretakers from the third SES quintile
were most likely to adhere to treatment compared with
the ﬁrst quintile, however there was no observed trend.
Although the majority of caretakers (409/444; 92.1%)
reported being advised on the frequency and duration for
ALu administration, the knowledge did not signiﬁcantly
inﬂuence the reported adherence. Basic education, offered
for 7 years in the country, did not inﬂuence adherence to
the treatment schedule.
No signiﬁcant difference in mean blood lumefantrine
concentrations was found between children whose
caretakers reported adherence and those who reported
non-adherence. The corresponding median levels were
286 nmol/l and 261 nmol/l, respectively (Figure 3). However, there was a wide variation in blood lumefantrine concentrations, ranging from 25 nmol/l (LoQ) to 9318 nmol/l
for the total group, and from 25 nmol/l to 1382 nmol/l for
those with reported non-adherence and from 25 nmol/l to
9318 nmol/l for those with reported adherence. Extreme
values (outliers) are not shown in Figure 3.

1500

1000

500

0
Reported non-adherence (n = 52)

Reported adherence (n = 392)

Figure 3. Distribution of lumefantrine blood concentration levels of study
children by reported adherence status (n = 444). Outliers not shown in
box plot.
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concentration cut-off point of 331 nmol/l (175 ng/ml),25
another study in Malawi reported patients were cured
even below this level.24 The difference might be explained
by possible variations in food intake,26 as the levels of
lumefantrine blood concentrations may increase 16-fold
in patients who took the drug with fatty food compared with without fat.27,28 Age-based dosage schedules
of ALu might also explain the unpredictable blood concentrations of lumefantrine, since the dose per kg may
vary widely between patients, as reported for the CQ/SP
combination.29 This underscores the need to monitor the
rate of adherence to treatment guidelines by providers
as well as treatment schedules among patients in rural
areas when implementing ALu treatment on a wide scale in
Africa.
The high reported adherence found in this study can be
explained by the availability of ALu in pre-packaged packets with pictorial instructions, which have been reported to
improve caretakers’ understanding of the schedule administration of the drug30 and hence they are more likely
to follow the provider’s advice.12,22,31 Studies conducted
when CQ resistance was high reported low adherence
levels,10,11 thus the highly efﬁcacious ALu used in the
present study might also explain the high reported level
of adherence to treatment.22
Non-adherence to ALu treatment found in this study
was mostly attributed to untimely dosing rather than
missing doses, contrary to concerns that caretakers might
discontinue treatment and save the remaining drugs for
later use.1,2 The high level of non-adherence in the last
two doses has also been reported in previous studies in
Tanzania and Malawi.8,24 This might be due to some caretakers perceiving that a child playing after an initial dose
is cured.16 Encouragingly, the low non-adherence level
might have little impact on the treatment strategy; however, there is a potential risk of building up pressure for
resistant strains over time.32
Children from the less poor households were found
to adhere to treatment better than poor patients. This
can partly be explained by the higher level of education among caretakers in the less poor households and
the tendency to own radios compared with the poor.9
This might have exposed them to more information
disseminated by the National Malaria Control Programme through radios and posters since the introduction
of ALu.
4.1. Methodological issues
Caretakers’ reports are subjective and were likely to
overestimate the level of reported adherence owing to possibilities of obtaining socially desirable responses.24 This
was minimised by explaining to the caretaker the objective of the study prior to the interviews. The fact that most
children were no longer sick on Day 7 reduced the likelihood of receiving desirable responses. This is in contrast
to reports of limited validity of caretakers’ reports when
interviewed at the health facilities.33 Pill count could not
be performed on Day 7 since most of the caretakers had
lost the packets. This limited the opportunity to triangulate
study ﬁndings. However, the fact that the results conform

to other community-based studies conducted in Tanzania
where pill count was performed indicates that misreporting might be minimal.
Recalling detailed information about how the drug was
administered after 7 days might result in data inaccuracy
as some details might be forgotten. We tried to minimise
this by following-up children weekly when the caretakers
could still remember the details. In addition, a sick child
tends to draw the attention of caretakers in a household,
thus increasing the likelihood of remembering events in
more details.
Blood lumefantrine concentrations would be useful
when studying adherence. However, the lack of a clear cutoff point24 and baseline levels limited a detailed analysis.
There were also other challenges resulting from applying
the method in a real-life situation. Several methodological issues were found in this study that could limit
the usefulness of the capillary blood sampling method
for lumefantrine in evaluating ALu effectiveness under
real-life conditions. These included the lack of baseline lumefantrine concentration, inability to control or
record food intake, and inconsistency in determining ALu
dosage where some prescribers based the dosage on child
weight while others used age. In addition, some prescribers used child weight measured on the same day
while others used the record found in the growth monitoring card, which could be outdated by several weeks or
months.
5. Conclusion
This study showed that the reported rate of adherence to ALu treatment was encouragingly high in rural
villages with or without a health facility. The large variability in lumefantrine concentrations cast doubt on the
rationale of using aged-based dosage schedules of ALu
as presently used in some facilities in Tanzania. Nonadherence was mainly attributed to off-schedule dosing
rather than taking a fewer number of doses and was
more pronounced in the last two doses. Despite the high
adherence, advocacy is still needed to improve caretakers’
understanding of the importance of adhering to the dose
schedule in order to reduce the risk of building up resistant
strains.
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